ASXL1 mutation is not an independent adverse prognosis predictor for survival in AML, whereas ASXL1-mut patients tend to have a poor prognosis if WBC count ≥50 × 10<sup>9</sup> /L, but they can benefit from HSCT. Here, ASXL1 is linked to acute myeloid leukemia.